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INTRODUCTION
 1 
 
Leprosy is a chronic granulomatous condition caused by Mycobacterium leprae 
mainly affecting the skin and peripheral nervous system. It also affects multiple organs based 
on the immunity of the person and bacterial load. Leprosy is divided into 5 different spectra 
based on the immunity of the person as lepromatous leprosy, borderline lepromatous, 
borderline borderline, borderline tuberculoid and tuberculoid by Ridley and Jopling. 
The normal course of disease is usually uneventful which will be abruptly changed 
by immunological reactions that could affect all the organs. There are three types of 
reactions. These reactions are more common in the borderline spectrum.  Type 1 reaction 
could be either upgrading or downgrading reaction. Type 2 reaction most commonly presents 
as erythema nodosum leprosum while it can affect internal organs also. Type 2 reaction 
occurs in borderline lepromatous amd lepromtous leprosy patients. 
The treatment for leprosy as advised by WHO is the multi-drug therapy regimen 
with Rifampicin, Dapsone and Clofazimine. The treatment of choice for reaction is steroids. 
But type 2 reaction has prolonged exacerbation and recurrence of lesions and hence results in 
steroid dependence and side effect due to steroids. This chronic course of type 2 reaction and 
the prolonged use of steroid increases the morbidity of leprosy even after the treatment for 
leprosy is completed. Thus a steroid sparing agent is needed to prevent recurrence of reaction 
and to avoid side effects of long term steroid.  
The drugs used as an alternative steroid in type 2 reaction are clofazimine and 
thalidomide. Azathioprine can be used as an adjunct to corticosteroids. 
  
 
 
 
 
REVIEW OF LITERATURE 
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Leprosy is a chronic inflammatory disease caused by Mycobacterium leprae. It 
mainly affects the skin and peripheral nervous system but can also affect muscle cells, 
chondrocytes and other internal organs. Though it is highly contagious, a large proportion of 
exposed people are naturally resistant to the disease
1
. 
The case definition of Leprosy according to the 8th WHO expert committee on 
Leprosy, 2010
2
 is, ―an individual who has not completed the course of treatment and has one 
or more of the following cardinal signs: 
1. Hypopigmented or reddish skin lesion(s) with definite loss of sensation, 
2. Nerve thickening with sensory impairment and 
3. Skin smear positive for acid fast bacilli.‖ 
The Ridley-Jopling clinical classification, most widely used, is based on the 
patient’s clinical state and immune status3. The disease is organized as lepromatous (LL), 
tuberculoid (TT) and dimorphous (borderline) leprosy. Dimorphous cases are classified as 
borderline lepromatous (BL), borderline tuberculoid (BT), or borderline borderline (BB). 
In 1981 the WHO introduced multidrug therapy(MDT) as first-line treatment for leprosy
4
.
 
 
Paucibacillary cases (PB-MDT): 
Duration: 6 doses given in a period of up to 9 months 
Adults: 
Monthly supervised dose of rifampicin 600 mg and dapsone 100 mg 
Daily self-administered dose of dapsone 100 mg 
 3 
 
Children:  
Monthly supervised dose of rifampicin 450 mg and dapsone 50 mg 
Daily self-administered dose of dapsone 50 mg 
 
Multibacillary cases (MB-MDT): 
Duration: 12 doses given in a period of up to 18 months 
Adults:  
Monthly supervised dose of rifampicin 600 mg, clofazimine 300mg and dapsone 100 
mg 
Daily self-administered dose of dapsone 100 mg and clofazimine 50mg 
Children:  
Monthly supervised dose of rifampicin 450 mg, clofazimine 150mg and dapsone 50 
mg 
Daily self-administered dose of dapsone 50 mg and clofazimine 50mg on alternate 
days 
 
LEPROSY REACTION: 
Leprosy reactions are immunologically mediated episodes of acute or subacute 
inflammation which alter the relatively uneventful chronic course of leprosy, affect the skin, 
nerves, mucous membrane and/or other sites and increase morbidity of the disease even after 
the multidrug therapy is completed
5
. 
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TYPES OF LEPROSY REACTION: 
Three types of reactions recognized are classified as follows: 
1. Type 1 reaction 
2. Type 2 reaction 
3. Lucio phenomenon 
 
Type 1 reaction: 
The type 1 reaction (T1R) is a delayed hypersensitivity reaction usually observed in 
borderline spectrum of the diseases except for very rare reports in lepromatous leprosy (LL)
6
. 
When there is increase in the immunity, the shift of the spectrum toward the tuberculoid pole 
is called upgrading or reversal reaction. When there is decrease in the immunity, the shift of 
the spectrum toward the lepromatous pole is called downgrading reaction. 
 
Type 2 reaction: 
This is an immune complex syndrome that is observed in LL and rarely in BL leprosy. 
 
The Lucio Phenomenon: 
This is observed in Lucio leprosy, uniformly diffuse shiny infiltrative, non-nodular 
form of LL that is mainly seen in Mexicans. It is due to necrosis of arterioles whose 
endothelium is massively invaded by Mycomacterium leprae
7
. 
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Table 1: Differences between type 1 reaction and type 2 reaction
5
 
 Type 1 reaction Type 2 reaction 
Hypersensitivity 
reaction 
Type IV Type III 
Spectrum affected BT, BB, BL, rarely LLs LL, rarely BL 
Constitutional sign None or rare  Common 
Type of the skin 
lesions 
Existing skin lesions (few or 
many or all) suddenly becomes 
reddish, swollen, warm, painful, 
tender 
Fresh red, painful, tender, 
cutaneous nodules, plaques. 
The existing lesions remain 
unchanged.  
Nerve involvement Nerves close to skin lesions 
may be enlarged, painful and 
tender due to acute neuritis with 
loss of nerve functions.  
Nerves may be affected but 
not as common or as severe 
as in type 1 reaction 
Eye involvement Corneal anesthesia and 
lagophthalmos (weakness of 
eyelid closure due to nerve 
damage)  
Internal diseases like iritis, 
iridocyclitis, glaucoma, 
cataract are common due to 
Ag-Ab complex 
Other organs Not affected May be affected 
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TYPE 2 REACTION: 
It is an immune complex syndrome (antigen-antibody reaction involving 
complement), causing inflammation of the skin, nerves and other organs. As the major 
clinical lesions on the skin are of erythema nodosum type, the term ―Erythema Nodosum 
Leprosum (ENL)‖ is used as an alternative for type 2 reaction(T2R).  
It can occur before, during or after treatment with anti-leprosy MDT
8,9,10
. Time of 
onset of the reactions collected by Indian Association of Leprosy in 2003 shows that 21% of 
all cases present at the beginning, 17.6% present within 6 months after starting MDT, 16.6% 
during second half of the year of MDT and 44.5% have the episodes even beyond 1 year of 
therapy
11
. 
It often has a protracted course with episodes of exacerbation and remission occurring over 7 
or more years, although the majority of exacerbation may last 12—24 months12. 
ENL reactions were reported to occur in more than 50% of LL cases and in about 
25% of BL cases in the pre-MDT era
13
. After the introduction of WHO-recommended MDT 
which includes clofazimine, the prevalence of ENL has decreased
14
.
 
 
Risk Factors
5
: 
• Lepromatous leprosy with skin infiltration8 
• Antileprosy drugs except clofazimine 
• Slit Skin Smear- Bacterial index of >4+8 
• Age < 40 years8 
 7 
 
• Intercurrent infections: Streptococcal, viral, intestinal parasites, filariasis, malaria 
• Trauma 
• Surgical intervention 
• Physical and mental stress 
• Protective immunization or vaccination 
• A strongly positive Mantoux test 
• Pregnancy and parturition 
• Ingestion of potassium iodide15 
• Alcohol & alcohol withdrawal 
 
Pathogenesis: 
During early phase of ENL, active macrophages in between the foamy cell destroy the inert 
foamy macrophages. Antigens released from these foamy macrophages are presented by new 
macrophages to the immune system stimulating cell mediated immunity. Those antigens 
which could not be engulfed by macrophages form immune complexes with the locally 
present antibodies which is deposited at various sites
16
.
 
There is increased expression of IL-4, 
IL-5, IL-13 and IL-10 cytokines (Th2 type response) and TNF-ɑ and INF-ɣ17,18. TNF- ɑ is 
known to be a pyrogen that raises the temperature and cause further tissue damage during 
ENL reaction
19
. It is found that both immune complex mediated (type III) and cell-mediated 
(type IV) immune response is present in ENL.  
 
 8 
 
Pathology: 
There is no definitive criterion for histopathological diagnosis of ENL and may vary 
according to the clinical spectrum the patient belongs to whether LL or BL type. 
While the most common histopathological features of active ENL lesions are increased 
vascularity with dilated capillaries in the upper dermis and intense infiltration with 
neutrophils in the lower dermis, especially surrounding blood vessels and invading vessel 
walls. Often neutrophilic infiltration may be so intense as to form microabscesses. Vasculitis 
is seen as a predominant feature in some cases. There is a reduction in the bacterial load with 
bacilli being fragmented and granular. As lesion heals, the neutrophils are gradually replaced 
by lymphocytes. In case of erythema necroticans obliterative angiitis and endarteritis leading 
to necrosis and ulceration may be seen
5
.  
 
Clinical features: 
Mode of onset
5 
1. Cutaneous Onset: appearance of crops of skin lesions before the appearance of 
constitutional signs and symptoms. 
2. Rheumatic Onset: In one-third of the cases, pain and swelling in the joints precede or are 
a component of other constitutional symptoms. 
3. Mixed Onset: Fever, joint pain and other constitutional signs and symptoms; and skin 
lesions develop together or fever immediately follows the appearance of skin lesions. 
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Skin- Erythema nodosum leprosum: 
These manifest as acute onset of crops of evanescent, pink colored tender papules, nodules or 
plaques, variable in size, painful and tender to touch. These lesions may present as dermal 
nodules and visible clearly or may be deep enough as subcutaneous nodules where they are 
palpable rather than visible. Some nodules may be ill defined and few to multiple may be 
dome-shaped, tender, warmer, and blanch with light finger pressure. Though they may 
appear anywhere on the skin, common sites are outer aspects of thighs, legs and face. The 
warmer areas like hairy scalp, axillae, groin and perineum are usually spared. If multiple 
they tend to be distributed bilaterally and symmetrically. They subside with desquamation. 
An individual ENL lesion after a period of 24–48 hours shows a change of color from 
pink/red to bluish and brownish and finally become dark in 7-10 days. New crops of ENL 
lesions appear as old lesions subside. And such fresh crops of ENL lesions usually appear in 
the evening when endogenous cortisol production is at its lowest
20
. ENL lesions may rarely 
become vesicular, pustular, bullous or necrotic and ulcerate when it is called as erythema 
nodosum necroticans
21,22
.
 
 
Systemic Manifestations:
 
Non-specific symptoms: 
Systemic manifestations like fever, malaise, prostration, headache, myalgia, joint pain and 
bone pain may precede the appearance of ENL. Fever is usually of intermittent type. As the 
reaction resolves, the temperature comes down. Bone pain usually confining to tibia is 
common
5
. 
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Nerve involvement:
 
 
Nerve damage may occur in T2R, but not as common as in T1R. In severe T2R, there may 
be swollen, painful and tender nerve trunks with loss of sensory and/or motor function. 
Careful nerve examination is essential to detect recent nerve function impairment of the 
respective affected nerves during and after each episode of T2R
5
.  
 
Acute myositis:  
Muscle involvement may be due to invasion by an extension of subcutaneous nodule through 
the deep fascia into the deep muscle. It feels woody hard. Rarely painful, tender, firm 
nodular lesions occur in the muscle fibers per se. The movement of the muscles becomes 
painful. Histopathology shows features of myositis
5
. 
 
Arthritis: 
 
In one-third of the cases, arthritis could be the presenting feature. It manifests as joint 
swelling, pain, tenderness and limitation of movements. Synovial effusions and bursitis are 
found in certain cases. The joints commonly affected in order of frequency are knee, 
metacarpophalangeal, interphalangeal, wrist and ankle joints. In recurrent T2R, nonparalytic 
deformities and limitation of movement at the joint and radiological changes may develop 
without adequate treatment
5
. 
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Nasal involvement: 
 
The infiltration and nodules present in the nasal septum and inferior turbinate may become 
edematous and swollen with blocking of the nose leading to difficulty in breathing. It may be 
associated with pain and epistaxis. In severe cases the nodules may ulcerate, leading to 
destruction of the cartilage, resulting in perforation of the septum
5
. 
 
Soft palate involvement: 
 
The soft palate, fauces, base of the uvula may be erythematous and may ulcerate. Repeated 
ulceration may lead to complete destruction of the cartilage
5
. 
 
Hard palate involvement: 
 
Hard palate also may be erythematous and swollen during reaction. Recurrent inflammation 
involves the bone with destruction and eventually results in perforation of the palate
5
. 
 
Involvement of larynx: 
 
Inflammatory reaction involving the larynx is a life threatening complication. Edema of 
epiglottis or vocal cords may lead to respiratory distress which sometimes necessitating 
tracheostomy as an emergency life-saving procedure
5
. 
 
Bone changes: 
 
• Osteoperiostitis: Particularly over the anterior aspect of the tibia is very common. There is 
severe bone pain and a soft tender swelling of the anterior aspect of the tibia. X-ray shows 
 12 
 
elevation of the periosteum at the site of swelling with soft tissue shadow below it. Repeated 
attacks may lead to laying down of new bone material with thickening of the cortex and 
increased anterior curvature of the bone. Besides tibia, it may also involve the phalanges 
(dactylitis) producing spindle-shaped swellings with tenderness. This can also occur at the 
upper end of ulna, lower end of fibula and the calcaneum
5
. 
• Osteoporosis: Osteoporosis may occur per se without accompanying arthritis. The 
phalanges and metacarpals are common sites involved, it has also been observed in long 
bones and ribs. It may occur as demineralization or as punched out areas of rarefaction seen 
in the Xrays. This may result in pathological fractures. The pull by the contracting muscles 
over such phalanges may lead to subarticular collapse of the bones. Demineralization is an 
acute process as proven by increased excretion of calcium in the urine during active reaction 
phase
5
. 
 
Lymph node enlargement: 
During ENL episodes, along with constitutional signs and symptoms there is often acute and 
painful enlargement of inguinal, axillary, cervical and epitrochlear lymph nodes. 
Occasionally, large abscesses are formed within lymph nodes which break open through the 
capsule and skin producing sinuses with discharge of pus
5
.  
 
Involvement of liver: 
Hepatic enlargement below the costal margin may be observed sometimes. The enlarged 
liver is soft and tender
5
. 
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Involvement of kidney: 
Acute glomerulonephritis in ENL is due to the immune complex deposition involving 
antigens of Mycobacterium leprae. However, in the majority of patients, the blood pressure 
is not elevated. Routine examination of urine reveals albuminuria, from a trace to 1+. 
Microscopic examination of the centrifuged urine sediment reveals plenty of red blood cells, 
pus cells, epithelial cells, epithelial casts and granular casts. In few cases, frank hematuria 
and rarely oliguria is noted. Kidney involvement in repeated attacks of T2R rarely ends 
fatally, while in others, repeated reaction favors the onset and progress to amyloidosis
5
. 
 
Suprarenal involvement: 
The blood pressure remains low due to hypofunctioning of the suprarenal gland during active 
reaction. Hence treatment with exogenous corticosteroid should be prompt and in adequate 
doses to compensate for the decrease of the endogenous hormone
5
. 
 
Acute epididymo-orchitis: 
There may be acute pain, tenderness and swelling in the scrotum due to acute inflammation 
of the testes and epididymis during reaction. There may be concomitant swelling, pain and 
tenderness of the breast also. Repeated attacks of reaction may result in testicular atrophy 
and gynecomastia which should be examined for in all the males
5
. 
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Hematological changes: 
Occasionally, a hemolytic crisis with a dangerous fall in the RBC count and hemoglobin may 
happen. There is sudden pallor and the patient develops breathlessness on the slightest 
exertion. This condition calls for emergency treatment with steroids and blood transfusion. 
Megaloblastic anemia has been documented possibly due to the toxic and/or depressive 
effect on the bone marrow. Hence there may be dimorphic anemia on peripheral smear
5
. 
 
Grading of Type 2 reaction: 
Mild reaction: 
1. Skin lesions and extent of involvement- Few lesions  
2.  Ulceration/necrosis of skin lesion- Absent  
3.  Constitutional symptoms like fever, arthralgia or fever- Absent 
4.  Neuritis- Absent  
5.  Edema of limbs- Mild  
6.  Eye involvement- Absent  
7.  Recurrent ENL- Nil 
8. Tender lymphadenopathy- Absent  
9. Systemic involvement (like epididymo-orchitis)- Absent 
10. Response to oral steroids- Usually responds in 6 weeks  
 
  
 15 
 
Severe reaction: 
1. Skin lesions and extent of involvement- Multiple red, painful nodules in skin 
2. Ulceration/necrosis of skin lesion- Present 
3. Constitutional symptoms like fever, arthralgia or fever- Present 
4. Neuritis- Pain and tenderness in one or more nerves 
5. Edema of limbs- Marked edema of the hands, feet or face 
6. Eye involvement- May be present 
7. Recurrent ENL- Four or more episodes in a year 
8. Tender lymphadenopathy- Frequently present  
9. Systemic involvement (like epididymo-orchitis)- May be present 
10. Response to oral steroids- Persists for long 
 
DIAGNOSIS: 
Clinical tests:  
 Ryrie Test: 
Stroking the sole of the foot with the back of a reflex hammer elicits a burning pain. It may 
also be noticed when the patient walks, which looks as if he is walking on hot coals
5
. 
 Ellis Test: 
Pain on squeezing the wrist during ENL. This may occur in reversal reaction only when the 
radial cutaneous nerve is involved and tender
5
. 
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Clinical criteria: 
Classical ENL and other rarer types of T2R with or without other constitutional features and 
associated systemic manifestations are diagnostic. Criteria for diagnosis of T2R (ENL) 
should include the major criterion or at least three minor criteria
23
.
 
Major criteria:  
A sudden eruption of tender (red) papules, nodules or plaques, which may ulcerate 
Minor criteria: 
1. Mild fever, the patient is unwell 
2. Tender enlarged nerves 
3. Increased loss of sensation or muscle power 
4. Arthritis 
5. Lymphadenitis 
6. Epididymo-orchitis 
7. Iridocyclitis or episcleritis 
8. Edema of extremities or face 
9. Positive Ryrie or Ellis test 
 
Laboratory changes:  
 Complete blood count- Leukocytosis 20,000/mm3 to 50,000/mm3 
 Erythrocyte sedimentation rate- markedly elevated 
 C-reactive protein- raised  
 17 
 
 Peripheral smear- Megaloblastic anemia. During hemolytic crisis dangerous fall in the 
red blood cell count and hemoglobin. 
 Liver function test: Mild rise in serum bilirubin and rise in serum transaminases. 
 Urine examination- albuminuria, RBC, pus cells, epithelial cells and epithelial cast 
 
Serological markers: 
 Chemokine ligand 11 (CCL11), a chemokine induced by IFN ɣ produced by monocytes, 
is identified as a potential plasma marker in type 2 reaction. CCL11 acts as a potent 
chemo attractant for eosinophils and Th2 lymphocytes, to the sites of inflammation
24
. 
 Elevated plasma IL7 were found which support the involvement of both B-cell and T-cell 
mediated  mechanisms in type 2 reaction
24
. 
 IL-6 is the only biomarker that is common for both T1LR and T2LR when compared 
with leprosy patients who are not in reaction
24
. 
 One of the acute-phase protein alpha-1-acid glycoprotein (AGP) was found in higher 
level in untreated ENL cases when compared with LL cases without reaction. Treatment 
with thalidomide has shown to reduce this level of AGP to normal
25
. 
 
TREATMENT OF TYPE 2 LEPROSY REACTION: 
The main aims in the management of T2LR are the control of acute inflammation, pain relief 
and prevention of further episodes or further damage to nerve and other organs
26
.
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I. Leprosy treatment: 
Multidrug therapy has to be continued without interruption. If not started, it should be started 
immediately along with specific treatment for T2R. If a course of MB-MDT is already 
completed, check for the disease activity and assess the need to re-start MB-MDT. 
 
II. Treat precipitating factors: 
Complete rest should be advised during reaction episodes. It is important to look for any 
precipitating factor which could be the trigger for reaction. It may be any intercurrent 
infection like streptococcal sore throat, viral infection like herpes simplex, intestinal 
parasites and protozoa filaria, malaria and physical and mental stress. All the infections need 
appropriate treatment with antibiotics. Psychological stress must be dealt by counseling by 
the doctor, nurses, or a trained counselor. Sedatives may help in reducing stress at times. 
 
III. Specific treatment of type 2 reaction: 
Mild type 2 reaction: 
Mild type 2 reactions are managed with analgesics and anti-inflammatory drugs such as 
aspirin and other NSAIDs
13
. 
 Aspirin 
Dose- 600 mg 6 hourly with meals and reduced slowly as signs and symptoms are 
brought under control.   
 19 
 
Mechanism of action- NSAIDs decrease prostaglandin synthesis and cause mild 
suppression of Ag-Ab reaction and Ab production, thus helping in alleviation of the 
reaction
27
. 
 
 Colchicine: 
Dose- 0.5 mg three times daily with a tapering course.  
Mechanism of action- It inhibits vascular injury by inhibiting neutrophil chemotaxis
27
.  
Adverse reactions- Bone marrow depression, peripheral neuritis, purpura, myopathy, 
loss of hair, reversible azoospermia and diarrhea
28
.
 
 
Severe type 2 reaction:  
1. Oral corticosteroids:  
Oral corticosteroids constitute the first line of management in severe T2R.  
Mechanisms of Action 
• Genomic: acting on gene and thence on protein synthesis, resulting in slow and delayed 
action. 
• Nongenomic: interacting with cell surface receptors and altering the physiochemical 
properties of cell membrane, resulting in early effects. 
The recent study on the relative genomic and nongenomic potencies of corticocorticoids 
suggests that methylprednisolone has a high ratio of nongenomic to genomic activity, and 
hence will be useful for early, high level of immunosuppression
29
.
 
It acts by inhibiting the early and late phases of inflammation in type 2 reaction.  
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 Decrease chemotaxis of neutrophils 
 Inhibit the enzyme prostaglandin synthetase and decreases prostaglandin level. 
 Suppression of cell-mediated immunity by depleting T-cells, especially Th-cells and 
resulting in decreased release of proinflammatory lymphokines. 
Dosage: 
Standard dose schedule for field purpose: World Health Organization, 1998, recommended 
12 weeks therapy with prednisolone for use at field level
30
.  
Dose              Weeks of treatment 
40 mg daily   1st and 2nd week 
30 mg daily   3rd and 4th week 
20 mg daily   5th and 6th week 
15 mg daily   7th and 8th week 
10 mg daily   9th and 10th week 
05 mg daily   11th and 12th week 
This standard steroid dose schedule of WHO, does not seem to give a sustained response
31
. 
Dosage at our institute level: Prednisolone started at a dose of 1 mg/kg/day till clinical 
improvement, and then tapered every week by 5–10 mg over 6–8 weeks until a maintenance 
dose of 20–30 mg which may be needed for several weeks and tapered slowly by 5mg to 
prevent recurrence of ENL. 
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Adverse effects 
It has been reported that patients receiving steroids for ENL develop more adverse effects 
compared to those with type 1 reaction which may be due to the longer duration of treatment 
needed in this group
32
.
 
This is particularly relevant in view of steroid dependency and the 
associated metabolic problems. The adverse effects seen most commonly are:
 
 Skin- striae, acne, purpura, ecchymosis, xerosis, persistent erythema of the skin in sun 
exposed areas and erythromelanoses. Among this, the last three skin complications can 
also be observed with clofazimine which is a part of MDT in MB leprosy
28
. 
 Cushingoid features due to the alteration in fat distribution, like buffalo hump, moon 
face, increased supraclavicular and suprasternal fat, protuberant and/or pendulous 
abdomen, flattening of buttocks and gynecomastia. Gynecomastia can also occur per se in 
LL or as a result of hormone change due to orchitis and liver involvement
28
.  
 Hair- hair loss, thinning of hair and the hair becoming brittle and fracturing along the 
shaft. Women may have hair growth on the beard area, on the arms and back, and 
coarsening of fine vellus hair
28
. 
 Gastrointestinal- hematemesis, peptic ulcer or perforation 
 Metabolic- diabetes mellitus, hypertension, edema due to sodium retention, hypokalemia 
due to increased potassium excretion, hyperlipidemias, secondary amenorrhea, decreased 
efficacy of anticoagulants and oral contraceptives. These side effects make a need for 
alternate or second line drugs, such as other immunosuppressive drugs
33
. 
 Ocular- cataracts and glaucoma. 
 22 
 
 Bone- Osteoporosis, pathological fractures, aseptic necrosis of the bone. 
 Central nervous system- psychosis and pseudotumor cerebri. 
 Opportunistic infections- tuberculosis, mucormycosis and chromoblastomycosis, have 
been reported in MB leprosy in T2R patients under prolonged corticosteroid and 
thalidomide
34
.
 
 
2. Clofazimine:  
Mechanism of action:  
 The biochemical basis for the antimicrobial action is yet unknown. It possibly acts by 
blocking the template function of DNA by binding preferentially to GC-rich region of 
mycobacterial (not mammalian) DNA
35
. 
 Increasing lysosomal enzyme synthesis and by increasing phagocytic capacity of 
macrophages
35
.  
 Stimulation of PGE2 synthesis, inhibition of neutrophil motility and selective suppression 
of Th-1 subtype of T-helper cells contribute to its role in T2R
36
.  
 Clofazimine selectively blocks the Kv1.3 potassium channel activity, perturbing the 
calcium channel, which leads to the inhibition of the calcineurin-nuclear factor of 
activated T-cells (NFAT) signaling pathway and providing an immunomodulatory 
effect
37
. 
Dosage:  
300 mg daily orally for a period of 1–3 months, followed by 200 mg daily for 3 months and 
100 mg daily for as long as the symptoms remain.  
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Side effects: 
 Skin- discoloration and darkening of the skin which is reversible, xerosis, persistent 
erythema of the skin in sun exposed areas and erythromelanoses
28
. 
 Precipitates to form crystals, especially in the intestinal mucosa, lymph nodes and in fatty 
tissue. The formation of such crystals in the gastrointestinal tract may lead to abdominal 
pain, nausea and diarrhea, and may be fatal in severe cases
28
. 
Disadvantage:  
Clofazimine is slow to act and hence does not relieve acute manifestations of reaction. 
 
3. Thalidomide:  
It is the treatment of choice for the management of severe T2R 
Mechanism of action: 
Thalidomide is a racemic glutamic acid analogue composed of two enantiomers R and S- 
thalidomide which interconvert under physiological conditions and have different properties. 
While S- enantiomer is a more potent suppressor of TNF-α release by stimulated peripheral 
mononuclear cells, R- enantiomer is a sedative. Thalidomide is able to suppress all clinical 
manifestations of T2R within 48–72 hours. 
Its action is faster and more effective than other anti-inflammatory drugs like aspirin, 
clofazimine and pentoxyphylline. Although response is faster to both thalidomide and 
prednisolone, improvement is much better and recurrence is much less frequent with 
thalidomide group
38
.
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Dosage:
  
 
200 mg twice daily, for 3–7 days or till reaction is under control, followed by tapering within 
3–4 weeks or more slowly if recurrence occurs as, 100 mg morning and 200 mg evening for 
4 weeks, 200 mg evening for 4 weeks, 100 mg evening for 4 weeks and 50 mg daily evening 
or 100 mg every alternate day evening for 8–12 weeks. 
Advantage:  
 Faster onset of action 
 Fewer adverse effects than corticosteroids 
 Good choice in recurrent or recalcitrant ENL. 
Disadvantage: 
 Teratogenic 
 Difficulty in monitoring at all healthcare levels 
 Costly 
 Nonavailability at all places. 
Adverse effects: 
• Teratogenicity: Intrauterine exposure to thalidomide during pregnancy between days 20 
and 36 after conception leads to development of phocomelia after which drug was banned 
from market
39
. The other associated abnormalities are deficient or absent ears, hearing loss, 
absent or extra digits, visual disturbances, cardiac, renal and GIT anomalies, cleft palate, 
saddle nose, etc. Thalidomide intercalate into and suppress the guanine rich promoter 
sequences of insulin growth factor-1 (IGF-1) and fibroblast growth factor (FGF) genes which 
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act in combination to stimulate limb initiation
40
. Reliable contraception is indicated even 
where there has been a history of infertility, unless it is due to hysterectomy or because the 
patient is postmenopausal for at least 24 months. Though it is also distributed in human 
semen after oral dosing, there is no report of teratogenicity so far caused through semen 
exposure
41
. 
• Neuropathy:  Peripheral neuropathy occurs in 20% individuals during first year of 
treatment
42
. Neuropathy correlates with the daily dosage and continues to progress for some 
time, even after stopping the therapy after which there is gradual improvement. However, it 
is permanent in 50% of the individuals. It is mainly a sensory loss characterized by painful 
paresthesia and numbness in a glove and stocking distribution. It affects the lower limbs 
initially, followed by upper limbs involvement. It may be associated with motor weakness 
also. Nerve conduction studies show a sensory, predominantly axonal neuropathy. 
Histopathology of nerves show loss of large myelinated fibers and little inflammation
43
. 
• Thromboembolism:  Reported in 3% of cases44. It increases to 14% when combined with 
dexamethasone
45
.  
• Somnolence:  Drowsiness is a common side effect and can be severe in 11% of patients46. It 
can be avoided by giving the drug at bed time. 
• Cutaneous adverse reactions:  Reported in 3% of cases46. Severe but rare cutaneous adverse 
effects are erythema multiforme, erythroderma and toxic epidermal necrolysis. 
• Other side effects: Constipation, nausea, dizziness, peripheral edema and hypothyroidism46. 
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4. Betamethasone pulse therapy:  
Slow intravenous infusion of 40 mg betamethasone daily in 5% dextrose for three 
consecutive days and repeated every 4 weeks has been recommended for recurrent ENL as it 
is better tolerated
47
.
 
 
5. Dexamethasone pulse therapy with azathioprine:  
This is considered as a daily steroid sparing regimen for steroid dependent chronic ENL 
reaction. It is given as 100 mg dexamethasone in 500 mL glucose IV infusion on three 
consecutive days, every month, along with 50 mg daily azathioprine
48
.  
 
6. Azathioprine: 
Used as corticosteroids sparing agents in leprosy reactions
49
.
 
Metabolism:
 
It is rapidly converted to 6-mercaptopurine (6-MP) upon absorption mainly in erythrocytes. 
The fate of 6-MP is determined by one of the following three pathways
50
: 
1. Anabolized to its active form, a purine analog 6-thioguanine (6-TG), by the enzyme 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT); 
2. Degraded by Thiopurine methyl transferase (TPMT) to inactive metabolites 
3. Degraded by Xanthine oxidase to inactive metabolites 
Reduced activity of either of the degradation pathways will shift more of the 6-MP into the 
active pathway, leading to excessive immunosuppression and an increased risk of bone 
marrow suppression
50
. 
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Mechanism of action:  
Structural similarity of 6-TG with endogenous purines allow it to be incorporated into DNA 
and RNA and inhibit purine synthesis.  It is a 
 It is a potent T-cell inhibitor 
 It inhibits B-cell proliferation and antibody production 
 It inhibit monocyte and neutrophil function 
 It is a strong anti-inflammatory by inhibiting TNF-alpha51 
Thus azathioprine by immunosuppressive effect and its effect on vasculitis is used in the 
management of type 2 leprosy reaction as a steroid sparing agent
48,5449,52,53
.
 
Pharmacology:  
>88% of azathioprine is absorbed through the GI tract after oral intake.  It does not cross the 
blood–brain barrier, but easily crosses the placental barrier. The peak plasma levels occur in 
< 2 hours. It is rapidly and extensively metabolized to active metabolite 6-TG
50
. The 
maximal clinical  immunosuppression is seen at around 8–12 weeks6254. 
Dosage: 2-3mg/kg/day 
Monitoring guidelines
54,55
 
Baseline 
• Pregnancy test (for women of childbearing potential) 
• Complete blood count (CBC) with platelet count 
• Liver function test (LFT) 
• Renal function test (RFT) 
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• Urine analysis 
• Tuberculin skin test for high risk patients 
• TPMT assay- phenotypic and genotypic analysis. 
TPMT level           Azathioprine dose 
< 6.3 U/mL           avoid  
6.3–15 U/mL        1 mg/kg daily 
15.1–26.4 U/mL   2–2.5 mg/kg daily 
Follow-up 
• Annual complete physical examination with attention to lymphoma and squamous cell 
carcinoma 
• Laboratory (biweekly for the first 2 months, every 2–3 months thereafter) 
• Complete blood count with differential count 
• Liver function tests especially transaminases 
• Renal function test- GFR < 10 mL/min- reduce dose by 50%; GFR 10–50 
mL/min- reduce dose by 25%.   
Side effects
50,55
: 
 Myelosuppression  
Neutropenia, agranulocytosis, pancytopenia rarely. Risk factor- reduced or absent TPMT 
activity. Cessation of the drug to be strongly considered if blood counts reduce 
significantly as WBC <3500–4000/mm3, hemoglobin <10 g/dL, platelets <100 000/mm3. 
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 Infections 
Human papilloma virus, herpes simplex, scabies. Risk factor- high doses of azathioprine 
or those on multiple immunosuppressive agents. 
 Malignancy 
Cutaneous squamous cell carcinoma, lymphoma. Risk factors are ethnicity, duration of 
treatment, level of immunosuppression, underlying disease state 
 Teratogenicity 
Category D in pregnancy as it crosses placenta and may rarely cause organ malformation 
 Hypersensitivity syndrome 
Morbilliform, purpura, erythema multiforme, urticaria, angioedema may typically 
develop between 1 and 4 weeks after starting therapy especially who are simultaneously 
receiving cyclosporine or methotrexate therapy. Rechallenge with the drug is 
contraindicated. 
 Gastritis 
Most common adverse effects, occurs between the first and tenth days of therapy. 
Prevention- reducing the dose, dividing the dose, and taking azathioprine with food 
 Pancreatitis- rarely 
 Liver transaminase elevation, rarely life-threatening hepatic damage 
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7. Pentoxifylline:  
A methyl xanthine derivative used in the treatment of peripheral vascular diseases.  
Mechanism of action- it inhibits the production of TNF-α  
Dose- 1,200 mg daily is  
Disadvantage- it is not as effective as thalidomide.  
Advantage- Good option for patients with human immunodeficiency virus (HIV) coinfection 
where long-term steroids and other immunosuppressants are contraindicated
56
.
 
 
8. Cyclosporine A: 
Mechanism of action- Inhibit T-helper cells  
No consistent result 
 
9. Methotrexate:  
Mechanism of action- increasing the adenosine levels, reducing proinflammatory cytokines 
and increasing the levels of anti-inflammatory cytokines.  
It is an effective steroid sparing agent when used in a case of steroid resistant ENL
57
.
 
 
10. Plasma exchange:  
Removes Ag, Ab and immune complexes from the blood and helpful in difficult cases. But 
availability and cost is a hindrance.  
 
11. Mycophenolate mofetil: no promising results 
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12. Leukotriene Inhibitors (Zafirlukast, Montelukast) 
Dose of 40 mg twice daily was found to be effective
58
.
 
 
13. Thalidomide Derivatives( Lenalidomide, Pomalidomide) 
More potent than thalidomide and no adverse effects but require human clinical trials. 
14. Anti-TNF-α agents(Infliximab, Etanercept, Adalimumab) 
Infliximab was reported to be effective in a case of recurrent ENL without any 
complications
59
.
 
 
Etanercept was found effective in ENL patient who failed to respond adequately to 
conventional therapy over a 6-year period
60
.  
TNF-α blockade carries an increased risk of fungal infection, Mycobacterium tuberculosis 
and precipitation of type 1 leprosy reaction on withdrawal
61
.
 
 
IV. Treatment of other complications28: 
 Physiotherapy for motor deficit 
 Splints for resting affected nerve 
 Surgical correction of any deformity 
 Acute iridocyclitis- Oral/local steroids (eg: 1% hydrocortisone, hourly; eye drops at 
morning and eye ointment at night), atropine eye drops twice daily 
 Acute epididymo-orchitis- Rest, oral steroids, scrotal suspensory bandage
    
 
 
 
 
METHODOLOGY
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OBJECTIVE / AIM  
To determine the efficacy of azathioprine in controlling Type 2 leprosy reaction along with 
steroids and their use as a steroid sparing agent. 
 
METHODOLOGY  
Study design: Interventional study 
Place of study: Department of Dermatology,  
Madras Medical College/Rajiv Gandhi Government General Hospital,  
Chennai- 3. 
Period of study: one year (August 2017- July 2018) 
Sample size: 40 
Inclusion criteria:  
1. Patients of above 15 years and below 60 years of age.  
2. Patients of both sexes.  
3. Patients willing for azathioprine and regular blood tests  
4. Patients willing for follow-up every 2 weeks  
Exclusion criteria:  
1. Children below 15 years, elderly patients more than 60 years  
2. Pregnant and lactating women.  
3. Patients who were not willing to come for follow-up.  
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4. Any serious systemic illness (uncontrolled hypertension, uncontrolled Diabetes 
mellitus, Tuberculosis, HIV, any malignancy etc.,)  
5. Hypersensitivity to azathioprine  
6. Reduced blood counts (WBC <3500/cu.mm, hemoglobin <10 g/dL, platelets 
<100000/cu.mm)  
7. Elevated liver transaminases  
 
SCREENING PROCEDURES/VISITS:  
Any patient fitting the criteria attending Hansen outpatient of Dermatology department and 
having signs and symptoms of Type 2 leprosy reaction were selected for the study.  
Detailed case history of each patient with reference to the duration of illness, anti leprosy 
treatment, anti reaction treatment and other comorbidities were noted.  
Clinical features like nerve involvement, trophic changes and other associated cutaneous 
disorders were noted. Thorough clinical examination and slit skin smear study was done. 
Blood investigations (complete blood count, renal function test, liver function test) and 
ultrasound abdomen were taken.  In doubtful cases, skin biopsy was done.  
Patients were either already on steroid or were started on steroid based on the severity of 
reaction. MB-MDT was given to patients with active disease. Azathioprine was started at a 
dose of 2mg/kg/day after proper evaluation.  
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FOLLOW UP PROCEDURES/VISITS:  
Patients were reviewed every 2weeks to check for the severity of reaction and change in drug 
dosage level. Steroid (prednisolone) was tapered by 10mg every 2-4 weeks initially till 20mg 
and then tapered by 5mg every 4-6 weeks. Steroid dose was increased to previous level when 
patients had new lesions on follow up. Steroid was completely stopped if there was no 
reaction or new lesion at 10mg alternate dose for 6-8 weeks. Azathioprine was continued 
even after steroids were stopped. Regular monitoring was done by repeating blood 
investigations (complete blood count, renal function test, liver function test) at proper 
interval.  
 
STATISTICAL ANALYSIS: 
The collected data was entered for analysis in Microsoft Excel. This data was exported to 
IBM Statistical Package for Social Sciences software (SPSS) version 23.0. Mean, standard 
deviations and range were employed to describe continuous variables, while frequency 
distributions were obtained for dichotomous variables. Chi square test was done to analyze 
the difference in response among various groups. 
 
ETHICAL ISSUES: 
Institutional ethics committee of Madras Medical College reviewed the study proposal for 
ethical consideration and approval of the committee was obtained prior to the study.
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Table 2: Spectrum 
Spectrum N (%) 
BL 19 (48%) 
LL 21 (52%) 
 
 
In this study, 48% of patients with T2R belonged to Borderline lepromatous spectrum and 
52% belonged to Lepromatous leprosy spectrum.  
48% 
52% 
SPECTRUM 
BL LL
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Table 3: Gender 
 BL LL Total  
Female 6(46%) 7(54%) 13 (33%) 
Male 13(48%) 14(52%) 27 (67%) 
 
 
 
Among 40 patients, 27 were male and only 13 were female. Male: female ratio in this study 
is 2.07:1. It is similar in both spectra. 
  
67% 
33% 
GENDER 
Male Female
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Table 4: Age group 
Age group (years) N (%) 
20-30 6(15%) 
30-40 18(45%) 
40-50 11(28%) 
50-60 5(12%) 
 
 
In this study, about 45% of patients were between 30-40 years and only 15% and 12% of the 
patients were less than 30 years and more than 50 years respectively. Minimum age at 
presentation was 20 years and maximum age at presentation was 55 years. Mean age at 
presentation was 37.48 years. 
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Table 5: Hansen’s disease 
Spectrum Old treated New case 
BL 9 (47%) 10 (53%) 
LL 14 (67%) 7 (33%) 
TOTAL 23 (58%) 17 (42%) 
 
 
In this study, old treated case of Hansen disease presenting with ENL was common than new 
cases of Hansen presenting with ENL in a ratio of 1.35:1. Among the old treated cases, LL 
spectrum was more common (67%) while among the new cases, BL spectrum was more 
common (53%). 
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Table 6: Treatment for Hansen (MB-MDT) 
MB-MDT N (%) 
Completed 21(52.5%) 
New 17(42.5%) 
Restarted 2(5%) 
 
 
Among 23 patients who had completed MB-MDT, it was restarted in 2 patients 
suspecting relapse. So 19 patients were on MB-MDT during the study and 21 had 
completed MB-MDT. 
  
52% 
43% 
5% 
MB-MDT 
Completed
New
Restarted
 40 
 
Table 7: Time interval between MB-MDT completion and enrolment to study 
MB-MDT completion Total  BL LL 
<1 year back 4(19%) 2(25%) 2(15%) 
1 year back 6(29%) 2(25%) 4(31%) 
2 years back 5(24%) 2(25%) 3(23%) 
3 years back 5(24%) 2(25%) 3(23%) 
4 years back 1(4%) 0 1(8%) 
 
 
In this study, among 21 patients in T2 R who had completed MB-MDT, most of them (29%) 
had completed it 1 year back and only 1 patient (4%) had completed it 4 years back and he 
belonged to LL spectrum. 
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Table 8: Duration of MB-MDT at the time of enrolment to study 
MD-MDT dose Total 
 N (%) 
BL  
N (%) 
LL  
N (%) 
<3 Month 8(42%) 5(46%) 3(37%) 
3-6 Month 5(26%) 4(36%) 1(13%) 
6-9 Month 3(16%) 1(9%) 2(24%) 
9-12 Month 2(11%) 1(9%) 1(13%) 
>12 Month 1(5%) 0 1(13%) 
  
 
In this study, among 19 patients with T2R who were on MB-MDT, most of them (42%) were 
on MB-MDT for less than 3 months duration and only 1 patient (5%) was on MB-MDT for 
more than 1 year (20
th
 dose) and belonged to LL spectrum. 
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Table 9: Hansen’s disease duration (Time since the patient noticed the disease) 
Hansen Duration N (%) 
0-6 months 6(12%) 
6-12 months 7(18%) 
12-24 months 15(38%) 
24-36 months 4(10%) 
36-48 months 4(10%) 
>48 months 5(12%) 
 
 
In this study, 38% of patients had noticed Hansen’s disease 1-2 years back. Mean duration of 
Hansen’s disease since the patient had noticed was 26.03 months while it was 23.42 months 
in BL spectrum and 28.38 months in LL spectrum. 
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Table 10: ENL distribution among spectrum 
 BL LL Total 
Recurrent 7(37%) 7(33%) 14(35%) 
New 12(63%) 14(67%) 26(65%) 
 
 
In this study, 63% patients were new cases of ENL while only 37% were recurrent cases of 
ENL. There was not much difference in both spectra. 
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Table 11: Duration of ENL 
ENL-Duration Total BL LL Recurrent  New 
<3 months 19(48%) 10(51%) 9(42%) 0 19(47%) 
3-6 months 4(10%) 2(11%) 2(10%) 0 4(10%) 
6-12 months 4(10%) 2(11%) 2(10%) 2(14%) 2(5%) 
1-2 years 5(12%) 2(11%) 3(14%) 4(29%) 1(3%) 
>2 years 8(20%) 3(16%) 5(24%) 8(57%) 0 
 
 
In this study, almost half of the patients (48%) had ENL for less than 3 months duration. 
Same was with BL (51%), LL (42%) and new case of ENL (47%). In patients with recurrent 
episodes of ENL 57% patients had ENL for more than 2 years.  The average duration of ENL 
in this study was 12.48 months. It was only 10.63 months in BL spectrum while it was 14.14 
months in LL spectrum. In new cases it was only 3.76 months while it was 28.85 months in 
recurrent cases. 
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Table 12: Duration of recurrent ENL 
Recurrent N (%) 
1-2 years 4(28%) 
2-3 years 4(28%) 
3-4 years 5(36%) 
>4 years 1(8%) 
 
 
Among 14 patients with recurrent ENL, most patients (36%) had recurrent episodes of ENL 
over 3-4 years while it was less common (8%) beyond 4 years. 
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Table 13: Time interval between onset of ENL and Hansen’s disease 
Hansen 
duration  at 
onset of ENL 
Total BL LL Recurrent New 
<6months 9(22%) 4(21%) 5(24%) 3(21%) 6(23%) 
6months-1year 19(48%) 10(53%) 9(43%) 8(58%) 11(42%) 
1-2years 8(20%) 4(21%) 4(19%) 1(7%) 7(27%) 
>2years 4(10%) 1(5%) 3(14%) 2(14%) 2(8%) 
Mean (month) 13.9 12.89 14.80 13.5 14.11 
SD 13.47 10.96 15.62 13.76 13.58 
 
 
Almost half (48%) of ENL cases occurred after 6months-1 year of Hansen disease. The 
average duration of Hansen at the time of onset of ENL was 13.9 months. This average 
duration was almost similar in both spectra. 
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Table 14: Relationship between ENL and MB-MDT 
Onset of ENL Before starting MB-MDT After starting MB-MDT 
Total 16 (40%) 24 (60%) 
BL 9 (47%) 10 (53%) 
LL 7 (33%) 14 (67%) 
Recurrent 4 (28%) 10 (72%) 
New 12 (46%) 14 (54%) 
 
 
In this study, onset of ENL after starting MB-MDT (60%) was common than before starting 
MB-MDT (40%).  There was not much difference in BL spectrum while in LL spectrum it 
was more common after starting MB-MDT (67%). Recurrent cases were more common if 
ENL occurred after starting MB-MDT. 
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Table 14: Time of onset of ENL after starting MB-MDT 
MB-MDT & 
onset of ENL 
Total BL LL Recurrent New 
<6months 5(21%) 1(10%) 4(29%) 0 5(36%) 
6months-1year 12(50%) 7(70%) 5(36%) 10(100%) 2(14%) 
1-2years 5(21%) 2(20%) 3(21%) 0 5(36%) 
>2years 2(8%) 0 2(14%) 0 2(14%) 
Mean (month) 11.3 13.54 15.14 10.2 15.92 
SD 5.45 10.47 12.91 2.89 13.17 
 
 
In this study, 50% cases of ENL that occurred after starting MB-MDT had onset by 
6months-1 year of MB-MDT. The average duration of onset of ENL after starting MB-MDT 
was 11.3 months. This was least in new case of ENL (10.2 months) and highest in recurrent 
cases (15.92 months) 
<6months 
21% 
6months-1year 
50% 
1-2years 
21% 
>2years 
8% 
Time of onset of ENL after starting MB-MDT 
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Table 15: Duration of steroid usage before starting azathioprine 
 <1 month 1-3 months 3-6 months 6-12 months >1 year Mean (weeks) 
Total  6(15%) 20(50%) 7(17%) 5(13%) 2(5%) 16.93 
BL 4(21%) 8(42%) 4(21%) 3(16%) 0 14.37 
LL 2(10%) 12(56%) 3(14%) 2(10%) 2(10%) 19.25 
Recurrent 1(7%) 5(36%) 4(29%) 3(21%) 1(7%) 21.83 
New 5(19%) 15(58%) 3(11%) 2(8%) 1(4%) 13.03 
Completed 
MB-MDT 
2(9%) 9(43%) 4(19%) 5(24%) 1(5%) 19.66 
On MB-MDT 4(21%) 11(58%) 3(16%) 0 1(5%) 12.31 
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In this study, all the groups showed that almost half of the patients were on steroid for 1-3 
months. The average duration of steroid intake was 16.93 weeks. It was less in BL (14.37 
weeks) compared to LL (19.25 weeks). It was less in new case of ENL (13.03 weeks) and 
highest in recurrent cases (24.14 weeks). It was least in patients who were on MB-MDT 
(12.31 weeks) than those who had completed MB-MDT (19.66 weeks). 
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Table 16: Baseline daily steroid dosage [1 tablet of Prednisolone= 5mg] 
Baseline daily steroid 
dosage 
Mean (SD) 
Total 5.27 (1.43) 
BL 5.36 (1.21) 
LL 5.19 (1.63) 
Recurrent 5.50 (1.91) 
New 5.15 (1.12) 
Completed MB-MDT 5.28 (1.67) 
On MB-MDT 5.26 (1.14) 
 
 
In this study, mean daily dose of steroid at baseline (start of study) was 5.27 tablets. This was 
almost similar in all scenarios under study.
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Table 17: Average steroid daily dosage at follow up [1 tablet of Prednisolone= 5mg] after 
administering azathioprine 100mg/day 
Follow up Baseline 2
nd
 month 4
th
 month 6
th
 month 8
th
 month 
Total  5.27(1.43) 4.17(1.17) 3.52(1.21) 2.82(1.40) 2.02(1.83) 
BL 5.36(1.17) 4.31(0.97) 3.42(1.09) 2.84(0.98) 1.73(1.58) 
LL 5.19(1.59) 4.04(1.29) 3.61(1.29) 2.80(1.84) 2.28(1.95) 
Recurrent 5.50(1.84) 4.07(0.96) 3.85(1.35) 3.28(1.53) 3(1.41) 
New 5.15(1.09) 4.2(1.24) 3.34(1.07) 2.57(1.41) 1.5(1.78) 
Completed 
MB-MDT 
5.28(1.63) 4.09(1.19) 3.61(1.29) 3.04(1.49) 2.71(1.57) 
On MB-MDT 5.26(1.11) 4.26(1.11) 3.42(1.09) 2.57(1.46) 1.26(1.74) 
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In this study, average daily steroid dose (Prednisolone 5mg tablets) on follow up after 
administering azathioprine 100mg/day was 4.17 tablets at 2
nd
 month, 3.52 tablets at 4
th
 
month, 2.82 tablets at 6
th
 month and 2.02 tablets at 8
th
 month. Among BL and LL patients, 
BL patients responded better with lower doses of steroid at the end of 8 months. Among 
recurrent and new cases of ENL, new patients responded much better and earlier with lower 
dose of steroid. Comparing patients who were on MB-MDT with who had completed MB-
MDT, it was found that those who were on MB-MDT responded earlier and better. 
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Table 18: Final response 
Response at 8
th
 month No. of patients 
Yes (Stopped steroid) 15 (37%) 
No (Continuing steroid) 25 (63%) 
 
  
 
In this study, after initiating azathioprine steroid could be tapered and stopped only in 37% 
of patients; the remaining 63% of patients had to continue steroids but at a low dose. 
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Table 19: Response among spectrum 
Spectrum Yes No 
BL 7 12 
LL 8 13 
Chi-Square – 0.007 
p value – 0.952 (Not statistically significant) 
 
 
In this study, there was no significant statistical difference in the response to the addition of 
azathioprine between BL and LL spectrum. 
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Table 20: Response among gender 
Gender Yes No 
Male 12 15 
Female 3 10 
Chi-Square – 1.709 
p value – 0.191 (Not statistically significant) 
 
 
In this study, there was no significant statistical difference in the response to addition of 
azathioprine among male and female. 
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Table 20: Response among age group 
Age group Yes No 
20-30 years 4 2 
30-40 years 6 12 
40-50 years 2 9 
50-60 years 3 2 
Chi-Square (Fisher Exact Test) – 5.143 
p value – 0.161 (Not statistically significant) 
 
 
In this study, there was no significant statistical difference in response to addition of 
azathioprine among different age groups. 
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Table 21: Response among various Hansen duration 
Hansen duration Yes No 
0-6 months 4 2 
6-12 months 4 3 
1-2 years 4 11 
2-3 years 1 3 
3-4 years 0 4 
>4 years 2 3 
Chi-Square (Fisher Exact Test) – 6.816 
p value – 0.235 (Not statistically significant) 
 
 
Though there was no significant statistical difference in response to addition of azathioprine 
among patients with different duration of leprosy (time since patient noticed the disease). 
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Table 22: Response and MB-MDT 
MB-MDT Yes No 
Completed 4 17 
On treatment 11 8 
Chi-Square (Fisher Exact Test) – 6.423 
p value – 0.011 (Statistically significant) 
 
 
In this study, patients who were on MB-MDT responded better to addition of azathioprine 
than those who had already completed MB-MDT and this was significant statistically. 
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Table 23: Response among MB-MDT completed duration 
MB-MDT completed 
duration 
Yes No 
<1 year 0 4 
1 year back 2 4 
2 years back 0 5 
3 years back 2 3 
4 years back 0 1 
Chi-Square (Fisher Exact Test) – 4.571 
p value – 0.334 (Not statistically significant) 
 
 
No statistically significant difference was noted in the response to addition of azathioprine 
among patients with varied time interval after completion of MB-MDT. 
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Table 24: Response among MB-MDT dosage 
MB-MDT dose Yes No 
<3 months 5 3 
3-6 months 2 3 
6-9 months 2 1 
9-12 months 2 0 
>12 months 0 1 
Chi-Square (Fisher Exact Test) – 3.651 
p value – 0.455 (Not statistically significant) 
 
 
In this study, there was no significant statistical difference in response to addition of 
azathioprine among patients who were currently on various duration of MB-MDT treatment.
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Table 25: Response among ENL episode 
ENL Yes No 
Recurrence 2 12 
New 13 13 
Chi-Square (Fisher Exact Test) – 4.952 
p value – 0.026 (Statistically significant) 
 
 
In this study, new cases of ENL responded much better to addition of azathioprine than those 
patients with recurrent ENL and this was proven statistically also. 
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Table 26: Response among recurrent ENL 
Recurrent ENL duration Yes No 
<2 years 0 4 
2-3 years 0 4 
3-4 years 2 3 
>4 years 0 1 
Chi-Square (Fisher Exact Test) – 4.200 
p value – 0.240 (Not statistically significant) 
 
 
In this study, there was no statistically significant difference in response to addition of 
azathioprine among patients with various duration of recurrent ENL. 
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Table 27: Response among new ENL cases 
New ENL duration Yes No 
0-1 month 3 3 
1-3 months 8 5 
3-6 months 2 2 
>6 months 0 3 
Chi-Square (Fisher Exact Test) – 3.692 
p value – 0.297 (Not statistically significant) 
 
 
Though there was no statistically significant difference in response to addition of 
azathioprine among new cases of ENL with varying disease duration, patients seemed to 
respond better in early stages. 
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Table 28: Response among duration of ENL 
ENL duration Yes No 
<3 months 11 8 
3-6 months 2 2 
6-12 months 0 4 
1-2 years 0 5 
2-3 years 2 4 
3-4 years 0 2 
Chi-Square (Fisher Exact Test) – 10.283 
p value – 0.067 (Not statistically significant) 
 
 
In this study, there was no statistically significant difference in response to addition of 
azathioprine among patients with varying duration of ENL. But patients with lesser duration 
seemed to respond better.  
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Table 29: Response among onset of ENL in relation to Hansen 
Onset of ENL in relation to Hansen Yes No 
<6 months 5 4 
6 months- 1 year 5 14 
1-2 years 3 5 
>2 years 2 2 
Chi-Square (Fisher Exact Test) – 2.533 
p value – 0.469 (Not statistically significant) 
 
 
There was no statistically significant difference in response to addition of azathioprine 
among patients with various duration of onset of ENL in relation to leprosy. 
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Table 30: Response among onset of ENL in relationship with MB-MDT 
Onset of ENL Yes No 
Before starting MB-MDT 8 8 
After starting MB-MDT 7 17 
Chi-Square (Fisher Exact Test) – 1.778 
p value – 0.182 (Not statistically significant) 
 
 
Though there was no statistically significant difference in response to addition of 
azathioprine among onset of ENL in relation to MB-MDT, patients who initially presented 
with ENL had responded better than those who developed ENL after starting MB-MDT. 
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Table 31: Response among onset of ENL in relation to MB-MDT dose 
Onset of ENL in relation to MB-MDT dose Yes No 
<6 months 2 3 
6 months- 1 year 2 10 
1-2 years 2 3 
>2 years 1 1 
Chi-Square (Fisher Exact Test) – 1.896 
p value – 0.594 (Not statistically significant) 
 
 
In this study, there was no statistically significant difference in response to addition of 
azathioprine among patients who developed ENL after varied dose of MB-MDT.  
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Table 32: Response among baseline steroid dose 
Baseline steroid dose Yes No 
15mg 0 1 
20mg 8 7 
25mg 1 2 
30mg 5 14 
>30mg 1 1 
Chi-Square (Fisher Exact Test) – 2.850 
p value – 0.583 (Not statistically significant) 
 
 
There was no statistically significant difference in response to addition of azathioprine 
among patients with various baseline daily steroid dosages. 
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Table 33: Response among steroid duration 
Steroid duration Yes No 
<1 month 2 4 
1-3 months 10 10 
3-6 months 2 5 
6-12 months 0 5 
>1 year 1 1 
Chi-Square (Fisher Exact Test) – 4.749 
p value – 0.314 (Not statistically significant) 
 
 
There was no statistically significant difference in response to addition of azathioprine 
among patients with various duration of steroid usage before administering azathioprine. 
0
5
10
15
20
<1 month 1-3 months 3-6 months 6-12
months
>1 year
2 
10 
2 1 
4 
10 
5 
5 1 
Response among steroid duration 
No
Yes
  
 
 
 
 
 
CLINICAL IMAGES 
  
  
 
 
IMAGE 1: ENL LESION ON LOWER LEG 
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This study was carried out on 40 type 2 leprosy reaction patients diagnosed at leprosy 
outpatient department of RGGGH between August 2017 and July 2018.  
In this study, the number of patients was almost equal in both BL and LL spectrums; 
19 and 21 respectively. This is different from the study by Pocaterra et al (2006)
9
 which 
showed that type 2 leprosy reaction is more common in LL spectrum (76.7%) than BL 
spectrum (23.3%). This difference is probably due to the smaller sample size in this study 
(40) compared to that study of 116 patients. 
Among 40 patients in this study, 27 were male and only 13 were female with a male 
to female ratio of 2.07:1. This shows the male preponderance in type 2 reaction. This is 
similar to studies by Choudhary et al (2015)
62
, Nigam et al (1975)
67
 and Gupta et al (2017)
66
 
which showed a male to female ratio of 2:1, 3:1 and 4.25:1 respectively. 
Minimum age at presentation was 20 years and maximum age at presentation was 55 
years in this study. While a study by Gupta et al (2017)
66
 had minimum age of 12 years and 
maximum age of 67 years, we did not see patients less than 20 years of age and more than 60 
years of age. 
Mean age at presentation was 37.48 years. This is similar to a study by Pocaterra et al 
(2006)
9
 which showed average age at presentation was 34.7 years.  
About 45% of patients in this study were between 30-40 years. The age group31-40 
years was found to be common in a study by Gupta et al (2017)
66
 also.  
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In this study, 63% patients were new cases of ENL while only 37% were recurrent 
cases of ENL. This is in contrast to the study by Choudhary et al (2015)
62
 and Gupta et al 
(2017)
66
 that found 63% and 66% had recurrent ENL. 
Among the recurrent cases, 57% showed recurrent episodes beyond 2 years with an 
average duration of 28.85 months. A study by Kumar et al (2004)
12
 showed that most of the 
recurrent episodes last for 12-24 months which is different from this study. 
Onset of ENL after starting MB-MDT (60%) was common than onset of ENL before 
starting MB-MDT (40%) in this study. This is similar to a study by Nigam et al (1975)
67
 that 
had 64.4% of ENL cases after starting MB-MDT. Studies by Choudhary et al (2015)
62
 and 
Gupta et al (2017)
66
 also showed the risk of ENL after starting MBMDT but with much 
higher numbers of 77% and 95% respectively.  
There was not much difference in onset of ENL after starting MB-MDT in BL 
spectrum, but in LL spectrum it was more common after starting MB-MDT (67%) in this 
study. Also recurrent ENL were more common if ENL occurs after starting MB-MDT in this 
study. We could not get any studies to compare the onset of ENL with MB-MDT among the 
two spectra and recurrent ENL. 
In this study, 50% cases of ENL that occur after starting MB-MDT has onset by 
6months-1 year of MB-MDT and the average duration of onset of ENL after starting MB-
MDT was 11.3 months. While a study by Pocaterra et al (2006)
9
 found that onset ENL was 
common during first
 
year of treatment with MB-MDT, study by Gupta et al (2017)
66
 showed 
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that onset of ENL was more common during 1-6 months of MB-MDT which is in contrast to 
this study. 
Before administering azathioprine, average duration of daily steroid intake to keep the 
T2R under control was 16.93 weeks. It was less in BL (14.37 weeks) compared to LL (19.25 
weeks). It was least in patients who were then on MB-MDT (12.31 weeks) than those who 
had completed MB-MDT (19.66 weeks). Chronic and recurrent ENL patients who were on 
steroids were at greater risk of being steroid dependant as described by Mahajan at al 
(2003)
48
. 
Steroid dosage in this study is mentioned as the number of 5mg prednisolone tablets 
that the patients take. The average prednisolone tablets that the patients were taking at the 
start of this study were 5.27. After adding azathioprine 100mg/day the average daily dose of 
steroid reduced to 4.17 tablets at 2
nd
 month, 3.52 tablets at 4
th
 month, 2.82 tablets at 6
th
 
month and 2.02 tablets at 8
th
 month. BL patients responded better with lower doses of steroid 
at the end of 8 months. New cases (first episode) of ENL responded much better and earlier 
with low doses of steroid than recurrent ENL patients. The patients who were on MB-MDT 
responded earlier and better than those who had completed MB-MDT. These findings are 
comparable to a study by Mahajan at al (2003)
48 
which found that ENL reaction can be 
controlled at low dose of steroid with minimal side effect when combined with azathioprine. 
In this study, adequate response was considered when reaction was completely under 
control with azathioprine alone after tapering and stopping steroids. Among 40 patients, 
steroid could be tapered and stopped and maintained with azathioprine in 37% of patients 
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only and remaining 63% of patients continued to take steroids but at a low dose along with 
azathioprine to prevent new ENL lesions. This is also proved in a study by Britton et al 
(1998)
64
 which showed that azathioprine could be used only as an adjunct with 
corticosteroid. 
The new cases of ENL responded to addition of azathioprine much better than those 
patients who had recurrent episodes of ENL. Also the patients for whom azathioprine was 
started at an earlier stage when steroid was used for lesser duration responded better. This is 
similar to a study of 9 cases by Salles et al(2011)
53
 which concluded that patients for whom 
treatment was begun with azathioprine at the first reaction episode required a much shorter 
treatment with high dose of steroid than those for whom azathioprine was started later. But 
case reports by Athreya et al (2007)
52
 and Verma et al (2006)
49
 showed reponse even among 
recurrent or chronic case. A study by Choudhary et al (2015)
62
 also showed response to 
azathioprine in recurrent cases but the duration of azathioprine used was longer (2 years). 
Those patients currently on MB-MDT showed adequate response to addition of 
azathioprine than those who had already completed MB-MDT. A study by Pocaterra et al 
(2006)
9
 says short course of clofazimine (100mg/day) has only little effect on reaction.
     
 
 
 
 
 
 
 
 
 
 
CONCLUSION
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In our study on type 2 leprosy reaction patients who were treated with steroid and 
azathioprine, the following conclusions were made 
 Distribution of type 2 leprosy reaction was equal among BL and LL spectrum. 
 Men were affected more commonly than women. 
 Most common age group involved was 30-40 years. 
 Recurrent ENL cases were less common than new cases of ENL. 
 Recurrent episodes can occur even beyond 2 years. 
 The onset of ENL after starting MB-MDT was more common than the onset of ENL 
before starting MB-MDT.  
 The ENL cases were common after 6 months-1 year of taking MB-MDT for leprosy. 
 Many patients continued to take steroid but at low dose after adding azathioprine. 
 The adequate response to azathioprine was better for new cases of ENL than recurrent 
cases of ENL. 
 The adequate response to azathioprine was better for patients who were on MB-MDT 
than who had completed MB-MDT therapy. 
Thus azathioprine can be used effectively as a steroid sparing agent in type 2 leprosy 
reaction if started at first episode of the reaction along with corticosteroid.
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ANNEXURE 
  
 
ABBREVIATIONS 
WHO- World Health Organisation 
LL- Lepromatous leprosy 
TT- Tuberculoid leprosy 
BB- Mid Borderline leprosy 
BL- Borderline Lepromtous leprosy 
BT- Borderline Tuberculoid leprosy 
MDT- Multi Drug Therapy 
MB-MDT- Multi Bacillary Multi Drug Therapy 
PB-MDT- Pauci Bacillary Multi Drug Therapy 
T1R- Type 1 Reaction 
T2R- Type 2 Reaction 
ENL- Erythema Nodosum Leprosum 
IL- Interleukin 
TNF- Tumor Necrosis Factor 
Th2- T-Helper cell-2 
CCL11- Chemokine Ligand 11 
  
 
AGP- Acid Glycoprotein 
NSAID- Non Steroid Anti Inflammatory Drug 
Ag- Ab- Antigen-Antibody 
DNA- Deoxyribo Nucleic Acid 
RNA- Ribo Nucleic Acid 
GC- Guanine Cytosine 
PGE2- Prostaglandin E2 
6MP- 6 Mercaptopurine 
6TG- 6 Thioguanine 
HGPRT- Hypoxanthine-Guanine Phosphoribosyltransferase 
TPMT- Thiopurine Methyl Transferase 
CBC- Complete Blood Count 
RFT- Renal Function Test 
LFT- Left Function Test 
GFR- Glomerular Filtration Rate 
HIV- Human Immunodeficiency Virus 
  
 
MASTER CHART 
S 
N
o 
Spe
ctr
um 
A
ge 
Se
x 
MBMDT Duratio
n Of 
Hansen 
Duration Of 
ENL 
Comorb
idities 
Base
line 
1mo
nth 
2mo
nth 
3mo
nth 
4mo
nth 
5mo
nth 
6mo
nth 
7mo
nth 
8mo
nth 
Steroid 
Duration 
1 BL 51 M 2nd month 4months 2months nil 4 4 3 5 4 3 2 2a/d 0 2months 
2 LL 48 M 1month back 18month 11months DM 4 4 3 2 4 3 2 4 3 8months 
3 LL 27 F restarted, 7th 
month 
3yrs 3yrs nil 6 4 3 4 3 2 2a/d 0 0 3months 
4 LL 32 M 3yrs back 6yrs 3yrs nil 4 3 2 3 2 2a/d 0 0 0 18months 
5 LL 32 M 10th month 1month 5months nil 4 6 4 3 2 2a/d 2 2a/d 0 5months 
6 BL 25 M 3yrs back 4yrs 3yrs on & off,  
1yr 
nil 3 2 4 3 2 5 4 3 4 1yr 
7 BL 42 M defaulter, 3rd 
month 
2yrs 3month nil 4 6 4 3 4 3 2 2ad 0 3months 
8 BL 40 F 2months back 15month
s 
1yr, now 1month thyroid 6 6 4 5 4 3 4 3 2 1month 
9 LL 37 F 3yrs back 4yrs 2months nil 6 4 2 4 4 6 4 5 4 2months 
10 LL 38 F 2nd month 3months 3months nil 5 6 4 3 2 3 2 2a/d  0 1month 
11 BL 30 M 2yrs back 3yrs 2.5yrs on & off, 
11months 
nil 4 6 4 6 5 4 5 4 3 11months 
12 BL 32 M 3months 1.5yrs 6months nil 4 4 3 4 3 2 2a/d 0 0 6months 
13 BL 22 M 1yr back 1yr 2months nil 6 6 4 3 2 2a/d 2 2a/d 0 2months 
14 BL 32 M 5months,restart 
apr 18 
2yrs 1.5yrs on & off, 
1month 
nil 6 6 4 6 4 4 3 4 3 1month 
15 LL 32 F 1st month 2months 2months nil 6 6 4 4 3 2 4 5 4 1month 
16 LL 40 M 2yrs back 3yrs 2.5yrs on & off, 
6months 
nil 4 4 3 2 6 4 6 5 4 6months 
17 LL 20 F 24months, 20th 
month 
2yrs 1.5yrs nil 6 4 6 8 6 11 8 6 5 1.5yrs 
18 LL 40 F 1yr back 2yrs 2months nil 4 3 2 2a/d 2 2a/d 0 0 0 1month 
19 BL 45 M 2times, 1yr back 5yrs 1yr, now 4month DM 4 3 5 4 3 4 3 2 3 4months 
20 BL 39 M 10th month 1yr 2months nil 6 4 3 5 4 3 2 2a/d 0 1month 
21 LL 55 M 6th month 2yrs 3months nil 4 4 3 5 4 3 2 2a/d 0 3months 
22 LL 36 M 1yr back 2yrs 1month nil 6 4 5 4 3 2 3 2 2a/d 1week 
23 LL 50 M 2months back 1.5yrs 1.5yrs, now 
2months 
nil 6 4 5 4 3 4 3 2 4 2weeks 
24 BL 48 M 1st month 6months 1month nil 6 4 4 3 2 2 3 2 2a/d 5months 
25 LL 52 M 1st month 3months 1month nil 4 6 4 3 2 3 2 2a/d 0 1month 
26 LL 36 M 4yrs back 5yrs 4yrs on & off DM 11 8 6 6 5 6 5 4 3 6months 
27 LL 35 M 3yrs back 5yrs 2months nil 6 6 4 4 3 2 1a/d 0 0 2months 
28 BL 29 M 1st month 2months 1month nil 6 4 6 5 4 3 2 2a/d 0 2weeks 
29 LL 30 M 2yrs back 3yrs 2yrs on & off, 
3months 
nil 5 4 5 6 5 4 3 4 5 2months 
30 BL 45 F 1st month 1yr 1month nil 5 4 6 5 4 3 2 3 2 2weeks 
31 BL 34 F 3yrs back 4.5yrs 3.5yrs on & off, 
4months 
nil 6 6 4 3 2 4 3 2 4 4months 
32 LL 35 F 1yr back 2yrs 1yr nil 4 6 6 4 3 4 3 2 4 8months 
33 LL 43 M 2yrs back 4yrs 3yrs on & off, 
3months 
nil 6 6 4 6 4 3 2 4 3 3months 
34 BL 28 M 1st month 1yr 1month nil 8 6 4 3 4 3 2 2a/d 0 2weeks 
35 BL 36 F 7th month 2yrs 2months nil 6 6 4 3 2 4 3 2 2a/d 2months 
36 BL 34 F 5th month 1yr 5months nil 6 4 6 4 3 4 3 2 4 2weeks 
37 LL 32 M 1yr back 2yrs 3months nil 4 6 4 6 5 4 3 2 4 3months 
38 BL 46 F 2yrs back 4yrs 2yrs on & off, 
7months 
nil 6 6 4 6 6 4 4 3 4 7months 
39 BL 51 M 8months back 2yrs 2months DM 6 4 6 4 3 2 4 3 2 1month 
40 LL 40 M 3rd month 1yr 4months nil 4 4 6 4 5 4 3 5 4 3months 
BL- Borderline lepromatous  
LL- Lepromatous leprosy 
M- Male  
F- Female 
DM- Diabetes mellitus 
a/d – Alternate days 
  
 
PROFORMA 
Case No :  
PATIENT DETAILS:  
Name :                                                         Age :               Sex:                               OP No :  
Address :                                                               Occupation :  
 
HISTORY:  
H/O raised reddish lesion  
Duration  
Transient/Persistent  
Recurrence  
Sites involved  
Ulcer  
H/O light coloured skin lesion  
H/O decreased sensation  
H/O inability to use any part of the body  
H/O ulcer  
H/O fever  
H/O joint pain  
H/O visual disturbance, redness of eye  
H/O epistaxis  
H/O change in voice  
  
 
H/O deformity  
H/O treatment for leprosy in the past  
H/O treatment for leprosy reaction  
H/O similar illness reaction in the past:  
H/O any systemic illness  
H/O any drug allergy 
CLINICAL EXAMINATION:  
GENERAL EXAMINATION:  
PR-         /min                     BP-          /            mm of Hg                                    Temp-  
Pallor-              Icterus-              Cyanosis-              Clubbing-                 Pedal edema-  
Generalised lymphadenopathy-  
CVS:  
RS:  
P/A:  
CNS:  
Bones and joints:  
DERMATOLOGICAL EXAMINATION:  
Hypopigmented patches:  
 
 
  
  
 
Erythematous nodules:  
 
 
Nerve examination:   
 
Motor system:  
 
 
Sensory system:  
 
 
Trophic changes:  
 
 
Deformities:  
 
 
Palms and soles:  
Mucosa:  
Hair and nail:  
Eye examination:  
  
 
INVESTIGATIONS:  
Slit skin smear  
Biopsy (if done)  
Complete blood count  
Renal function test  
Liver function test  
USG-Abdomen  
Chest X Ray 
TREATMENT:  
 
 
 
 
FOLLOW UP:  
Follow up at every 2 week:  
  
Side effects:  
Recurrence: 
  
  
 
INFORMATION SHEET 
TITLE: ROLE OF AZATHIOPRINE AS A STEROID SPARING AGENT IN TYPE 2 
LEPROSY REACTION  
Name of Investigator: Dr.P.Sneha Priya  
Name of Participant:  
Purpose of Research: The purpose of this study is to determine the efficacy of azathioprine 
in controlling Type 2 leprosy reaction along with steroids  
Study Design: Interventional Study  
Study Procedures: In this study patient’s history and examination will be done and slit skin 
smear and basic blood investigations will be taken. The patients are then grouped into 2 
groups and patients will be treated with systemic steroids (Tablet Prednisolone) and 
azathioprine.  
Possible Risks: Myelosuppression(Neutropenia, Agranulocytosis, pancytopenia); 
Infections(Human papilloma virus, herpes simplex, scabies); Teratogenicity; 
Hypersensitivity syndrome(morbilliform, purpura, erythema multiforme, urticaria, 
angioedema); Gastritis, Pancreatitis, Liver transaminase elevation  
Possible benefits:  
To patient: The patient will be provided with a steroid sparing agent that helps in tapering 
steoid dose and reduce the side effects of using long term steroids.  
To doctors & other people: The result of the study will help to determine the efficacy of 
azathioprine in type 2 leprosy reaction. This will help in providing better and complete 
treatment to other patients in future. 
  
 
Confidentiality of the information obtained from you:  
The privacy of the patients in the research will be maintained throughout the study. In the 
event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared.  
Can you decide to stop participating in the study?  
Taking part in this study is voluntary. You are free to decide whether to participate in this 
study or to withdraw at any time.  
How will your decision to not participate in the study affect you? 
Your decision will not result in any loss of benefits to which you are otherwise entitled.  
 
 
 
 
Signature of Investigator                                                                          Signature of 
Participant  
 
Date:  
Place: 
  
 
 
  
 
  
  
 
PATIENT CONSENT FORM 
Title of the study: ROLE OF AZATHIOPRINE AS A STEROID SPARING AGENT 
IN TYPE 2 LEPROSY REACTION  
Name of the Principal investigator: Dr.P.SNEHA PRIYA  
Name of the Institution: Rajiv Gandhi Government General Hospital, Chennai  
Patient’s Name  :
  
Age/Sex  :
  
Out patient no. : 
  
Patient may check (☑) these boxes  
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and doubts 
have been answered to my complete satisfaction.  
 
I understand that my/my son’s/daughter’s participation in the study is 
voluntary and that I am free to withdraw at any time without giving reason, 
without my legal rights being affected.  
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation to it, 
even if I withdraw from the study I agree to this access. However, I 
understand that my/ my son’s/ daughter’s identity will not be revealed in any 
 
 
 
 
  
 
information released to third parties or published, unless as required under 
the law. I agree not to restrict the use of any data or results that arise from 
this study.  
 
I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual 
symptoms.  
 
I hereby consent to participate in this study   
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests 
and to undergo treatment  
 
 
 
 
Signature/thumb impression  
Patient’s Name:  
Address:  
 
Signature of Investigator:  
Study Investigator’s Name: Dr.P.Sneha Priya 
 
 
Gaurdian’s name:  
Relation to the patient: 
 
 
 
  
 
 
  
 
  
  
 
 
  
  
 
CERTIFICATE - II  
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DR.P.SNEHA PRIYA with registration Number 201630008 for the award of M.D 
DERMATOLOGY, VENEREOLOGY & LEPROSY in the branch of XX.  I personally 
verified the urkund.com website for the purpose of plagiarism Check.  I found that the 
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percentage of plagiarism in the dissertation.  
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